[Immunotherapy of metastatic renal cell carcinoma: report of 28 cases].
OBJECTIVE
To determine the efficacy of IL-2, IFN and Furtulon in patients with metastatic renal cell carcinoma.


METHODS
During the induction phase of the treatment of 28 patients, which lasted 3 months, IL-2 and IFN were administered subcutaneously three times a week at doses of 5 - 20 MU/m(2) and 6 - 9 MU/m(2), Furtulon was administered at doses of 800 - 1,200 mg daily by oral during 28 days a month.


RESULTS
The response rate was 46.4%, including 4 complete response (CR), 9 presented with partial response (PR).


CONCLUSIONS
The three-drugs combination described in this study demonstrates activity. Based on the present data, combined biochemotherapy may be a promising new approach to the therapy of the metastatic renal cell carcinoma.
Wang
Hui-jun
HJ
Department of Urology, Peking Union Medical College Hospital, Beijing 100230, China.
Wang
Hai
H
Li
Han-zhong
HZ
Shi
Bing-bing
BB
Song
Zong-lu
ZL
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D007167:Immunotherapy; D007279:Injections, Subcutaneous; D007372:Interferons / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D016896:Treatment Outcome
D007376:Interleukin-2; D005467:Floxuridine; D007372:Interferons; C025034:doxifluridine